Andreas Geier

18.6k total citations
209 papers, 6.7k citations indexed

About

Andreas Geier is a scholar working on Epidemiology, Hepatology and Oncology. According to data from OpenAlex, Andreas Geier has authored 209 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Epidemiology, 78 papers in Hepatology and 57 papers in Oncology. Recurrent topics in Andreas Geier's work include Liver Disease Diagnosis and Treatment (99 papers), Drug Transport and Resistance Mechanisms (43 papers) and Hepatitis C virus research (26 papers). Andreas Geier is often cited by papers focused on Liver Disease Diagnosis and Treatment (99 papers), Drug Transport and Resistance Mechanisms (43 papers) and Hepatitis C virus research (26 papers). Andreas Geier collaborates with scholars based in Germany, Switzerland and United States. Andreas Geier's co-authors include Monika Rau, Christoph G. Dietrich, Siegfried Matern, Michael Trauner, Frank Lammert, Carsten Gartung, Beat Müllhaupt, Heike M. Hermanns, Daniel Jahn and Johannes Weiß and has published in prestigious journals such as The Lancet, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Andreas Geier

193 papers receiving 6.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Geier Germany 41 3.5k 2.4k 1.8k 1.6k 1.4k 209 6.7k
Henning Grønbæk Denmark 43 5.2k 1.5× 2.3k 0.9× 1.6k 0.9× 1.8k 1.1× 1.3k 1.0× 329 8.4k
Nahúm Méndez‐Sánchez Mexico 43 4.2k 1.2× 2.4k 1.0× 2.0k 1.2× 784 0.5× 1.1k 0.8× 302 7.8k
Takuji Torimura Japan 45 3.4k 1.0× 3.3k 1.4× 1.4k 0.8× 1.2k 0.7× 1.7k 1.3× 282 7.6k
Carolin Lackner Austria 41 2.9k 0.8× 1.5k 0.6× 2.4k 1.4× 1.3k 0.8× 1.6k 1.2× 98 7.6k
Misael Uribe Mexico 45 4.5k 1.3× 3.2k 1.3× 2.1k 1.2× 602 0.4× 960 0.7× 328 7.8k
Bilal Hameed United States 24 4.1k 1.2× 2.5k 1.0× 1.2k 0.7× 885 0.5× 857 0.6× 70 5.7k
Edoardo G. Giannini Italy 48 5.0k 1.4× 4.9k 2.0× 2.0k 1.1× 638 0.4× 777 0.6× 263 8.6k
Martin Wagner Austria 41 2.6k 0.7× 1.8k 0.7× 2.2k 1.3× 3.3k 2.0× 1.2k 0.8× 81 6.2k
Naga Chalasani United States 28 3.3k 0.9× 2.1k 0.9× 1.2k 0.7× 861 0.5× 731 0.5× 69 5.1k
Takumi Kawaguchi Japan 45 4.2k 1.2× 2.9k 1.2× 1.6k 0.9× 925 0.6× 2.2k 1.6× 290 8.4k

Countries citing papers authored by Andreas Geier

Since Specialization
Citations

This map shows the geographic impact of Andreas Geier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Geier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Geier more than expected).

Fields of papers citing papers by Andreas Geier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Geier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Geier. The network helps show where Andreas Geier may publish in the future.

Co-authorship network of co-authors of Andreas Geier

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Geier. A scholar is included among the top collaborators of Andreas Geier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Geier. Andreas Geier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khaled, Najib Ben, Julia Schneider, Alexander Weich, et al.. (2025). Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort. Alimentary Pharmacology & Therapeutics. 61(11). 1755–1766. 1 indexed citations
2.
Piseddu, Ignazio, Michael Karin, Julia Schneider, et al.. (2024). 202P The impact of statins and proton-pump inhibitors on immune checkpoint inhibition in patients with hepatocellular carcinoma. Annals of Oncology. 35. S89–S89.
3.
Geier, Andreas, Vasco Sequeira, Alexander Nickel, et al.. (2024). Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats. Nutrients. 16(6). 904–904. 6 indexed citations
4.
Goetze, Oliver, Aikaterini Papagianni, Caroline Morbach, et al.. (2024). Cardio-Hepatic Interaction in Cardiac Amyloidosis. Journal of Clinical Medicine. 13(5). 1440–1440. 1 indexed citations
5.
Bantel, Heike, Marcos Girala, Matthias P. Ebert, et al.. (2024). Evaluation of four chatbots in autoimmune liver disease: A comparative analysis. Annals of Hepatology. 30(1). 101537–101537. 6 indexed citations
6.
Teufel, Andreas, Andreas Geier, Christoph Sarrazin, et al.. (2023). Intersektorales Management von Patienten mit unklarer Leberwerterhöhung und nichtalkoholischer Fettlebererkrankung (NAFLD). Zeitschrift für Gastroenterologie. 61(8). 1028–1036. 1 indexed citations
7.
Reiter, Florian P., Cornelia Fießler, Ina Bergheim, et al.. (2023). Salt-Intake-Related Behavior Varies between Sexes and Is Strongly Associated with Daily Salt Consumption in Obese Patients at High Risk for MASLD. Nutrients. 15(18). 3942–3942. 12 indexed citations
8.
Geier, Andreas, et al.. (2023). Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions. British Journal of Clinical Pharmacology. 90(4). 942–958. 16 indexed citations
9.
Franck, Martin, Katharina John, Monika Rau, et al.. (2023). Hepatokine‐based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients. Liver International. 43(12). 2668–2679. 6 indexed citations
10.
Ye, Liangtao, Najib Ben Khaled, Peter Schirmacher, et al.. (2023). Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management. Liver Cancer. 13(1). 6–28. 15 indexed citations
11.
Lange, Christian M., Jonel Trebicka, Alexander L. Gerbes, et al.. (2023). Limited access to liver transplantation and TIPS despite high mortality, healthcare resource use and costs of cirrhosis in Germany. Liver International. 43(11). 2503–2512. 2 indexed citations
12.
John, Katharina, Martin Franck, Monika Rau, et al.. (2022). Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4. Journal of Clinical Medicine. 11(15). 4394–4394. 7 indexed citations
13.
Hermanns, Heike M., Óscar Briz, José M. Herranz, et al.. (2022). Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation. Cells. 11(24). 3983–3983. 5 indexed citations
14.
Petersen, Jörg, Wolf Peter Hofmann, Holger Hinrichsen, et al.. (2021). Real-World Clinical Management of Patients with Primary Biliary Cholangitis—A Retrospective Multicenter Study from Germany. Journal of Clinical Medicine. 10(5). 1061–1061. 13 indexed citations
15.
Stirnimann, Guido, Thomas Berg, Laurent Spahr, et al.. (2017). Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis. Alimentary Pharmacology & Therapeutics. 46(10). 981–991. 39 indexed citations
16.
Jahn, Daniel, Monika Rau, Heike M. Hermanns, & Andreas Geier. (2015). Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine & Growth Factor Reviews. 26(6). 625–635. 50 indexed citations
17.
Kajüter, Hiltraud, et al.. (2014). Kohortenstudie zur Krebsinzidenz bei Patienten mit Diabetes mellitus Typ 2: Record Linkage von kryptografierten Daten einer externen Kohorte mit Daten des Epidemiologischen Krebsregisters Nordrhein-Westfalen. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 57(1). 52–59.
18.
Frei, Pascal, Ulrike Held, Reto Kofmehl, et al.. (2013). Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon‐α and ribavirin in chronic hepatitis C virus patients. Liver International. 34(4). 551–557. 10 indexed citations
19.
Mertens, Joachim C., Bettina Saar, Joachim Kettenbach, et al.. (2011). 211 EFFECTS OF RADIOFREQUENCY ABLATION (RFA) IN COMBINATION WITH SORAFENIB IN A 2-TUMOR RAT MODEL OF HEPATOCELLULAR CARCINOMA. Journal of Hepatology. 54. S89–S89. 1 indexed citations
20.
Geier, Andreas, Christoph G. Dietrich, Tobias Grote, et al.. (2005). Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. Journal of Hepatology. 43(6). 1021–1030. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Henning Grønbæk Breakdown of academic impact, for papers by Nahúm Méndez‐Sánchez Breakdown of academic impact, for papers by Takuji Torimura Breakdown of academic impact, for papers by Carolin Lackner Breakdown of academic impact, for papers by Misael Uribe Breakdown of academic impact, for papers by Bilal Hameed Breakdown of academic impact, for papers by Edoardo G. Giannini Breakdown of academic impact, for papers by Martin Wagner Breakdown of academic impact, for papers by Naga Chalasani Breakdown of academic impact, for papers by Takumi Kawaguchi
Rankless by CCL
2026